Publications - Department of Law - Staff portal en-us PURE Extension (Web Department) 30 <![CDATA[Ulovlige aftaler]]> Torp, K.

De ulovlige aftaler analyseres i proces- og aftaleretligt perspektiv, og der opstilles på den baggrund en række retningslinjer for bedømmelsen af den brogede kreds af ulovlige aftaler. ]]>
Research Thu, 01 Jun 2023 07:29:07 +0200 cce33c57-4257-43da-8875-51d7088d7693
<![CDATA[De retlige rammer for anvendelse af blandingszoner]]> Basse, E. M., Elbæk, F. . Research Fri, 12 May 2023 07:29:07 +0200 ff5ffbdb-6b5e-44c6-ae47-281c8638c056 <![CDATA[EU judgments relating to company law]]> Sørensen, K. E. Communication Sun, 01 Jan 2023 07:29:07 +0100 44f1452f-6bc7-4af1-a3d1-b3a092fbc69c <![CDATA[Boganmeldelse: The Business Judgement Rule in Danish law]]> Sørensen, K. E. Communication Sun, 01 Jan 2023 07:29:07 +0100 a346d939-1ca7-4e8b-8130-cef546025f01 <![CDATA[På Englenes Vinger]]> Verdoner, S. A. Research Sun, 01 Aug 2021 07:29:07 +0200 adfa9c4d-b1fd-4528-badc-3762ada4e8fb <![CDATA[Kommunalret, 5. udg]]> Revsbech, K., Garde, J., Mørup, S. H. Research Sun, 01 Jan 2023 07:29:07 +0100 4c511696-9c85-43e4-8655-cf2cb26a6224 <![CDATA[Patient safety culture improves during an in situ simulation intervention]]> Schram, A., Paltved, C., Christensen, K. B., Kjaergaard-Andersen, G., Jensen, H. I., Kristensen, S. OBJECTIVES: This study aimed to investigate staff's perceptions of patient safety culture (PSC) in two Danish hospitals before and after an in situ simulation intervention.

DESIGN: A repeated cross-sectional intervention study.

SETTING: Two Danish hospitals. Hospital 1 performs emergency functions, whereas hospital 2 performs elective functions.

PARTICIPANTS: A total of 967 healthcare professionals were invited to participate in this study. 516 were employed in hospital 1 and 451 in hospital 2. Of these, 39 were trained as simulation instructors.

INTERVENTION: A 4-day simulation instructor course was applied. Emphasis was put on team training, communication and leadership. After the course, instructors performed simulation in the hospital environment. No systematic simulation was performed prior to the intervention.

MAIN OUTCOME MEASURES: The Safety Attitude Questionnaire investigating PSC was applied prior to the intervention and again 4 and 8 weeks after intervention. The proportion of participants with a positive attitude and mean scale scores were measured as main outcomes.

RESULTS: The response rate varied from 63.6% to 72.0% across surveys and hospitals. Baseline scores were generally lower for hospital 1. The proportion of staff with positive attitudes in hospital 1 improved by ≥5% in five of six safety culture dimensions, whereas only two dimensions improved by ≥5% in hospital 2. The mean scale scores improved significantly in five of six safety culture dimensions in hospital 1, while only one dimension improved significantly in hospital 2.

CONCLUSIONS: Safety attitude outcomes indicate an improvement in PSC from before to after the in situ simulation intervention period. However, it is possible that an effect is more profound in an acute care hospital versus an elective setting.

Research Mon, 01 Mar 2021 07:29:07 +0100 c8c47677-53c7-43ea-aea9-6ee379451c41
<![CDATA[Forvaltningspersonalet]]> Revsbech, K., Hemme, M. S., Mørup, S. H. Research Fri, 24 Mar 2023 07:29:07 +0100 d4fd61e2-e863-4d36-8d9f-ccce2914311f <![CDATA[P v O, Appeal decision, U.2022.796V.L.K.]]> Terkelsen, O. Research Sun, 01 Jan 2023 07:29:07 +0100 de354d50-b360-4783-bbe3-0b5a566ea083 <![CDATA[Climate Change hearings and the ECtHR]]> Pedersen, O. W. Research Tue, 04 Apr 2023 07:29:07 +0200 60273656-04ac-4c7b-9166-6e1c05946517 <![CDATA[Prison Leave and access to Justice: An insight into Danish and German Law in action]]> Storgaard, A., Graebsch, C. . court. In our analysis, we have compared Danish court cases with letters from German prisoners referring to their struggles with prison administrations and courts. The materials from both countries show more similarities than one would expect, given the significant differences between the substantive law in the two jurisdictions. While acknowledging the need for further empirical investigation, we introduce a concept we term "genuine justice", with the aim of paving the way for
other and more radical remedies supplementing the economic, legal and social measures already in place.
Research Mon, 06 Feb 2023 07:29:07 +0100 b9f8b8dc-cb15-457d-b0d9-784e6010786c
<![CDATA[Direktivforslaget om tilpasning af EU's naturlov ved fremtidig udbygning af vindmølleparker]]> Basse, E. M. Research Wed, 01 Mar 2023 07:29:07 +0100 69995372-dc86-4730-ab87-318f498cda8f <![CDATA[Anmeldelse af Mathias Mikkelsen, Forældelsesloven i lyset af Den Europæiske Menneskerettighedskonvention, Djøf Forlag, 2022]]> Terkelsen, O. Communication Wed, 01 Mar 2023 07:29:07 +0100 57f7efe3-a485-4194-b370-9d475bd48fb9 <![CDATA[Arbejdsmarkedets regler 2023]]> Communication Sun, 01 Jan 2023 07:29:07 +0100 e37b4e00-1738-4717-83ee-09e66084f115 <![CDATA[Varetektsfengsling av personer under 18 år]]> Storgaard, A., Fornes, I. Research Wed, 01 Feb 2023 07:29:07 +0100 ca04afc7-985c-49eb-9878-87e67c3b7776 <![CDATA[Børn og unge imellem hjælp og straf]]> Storgaard, A. Research Mon, 01 Aug 2022 07:29:07 +0200 02506a13-df86-4c41-8831-1fd582505605 <![CDATA[Immaterialret]]> Madsen, P. B. Research Sun, 01 Jan 2023 07:29:07 +0100 e6d5fbdc-6e7a-4387-bf22-4c387148f925 <![CDATA[Opsigelse af aftaler om leje af grunde og lokaler]]> Edlund, H. H. Research Wed, 15 Mar 2023 07:29:07 +0100 9274c8e6-c2c7-4926-9eee-012c3d03a468 <![CDATA[Preferential, Differential or Discriminatory?]]> Vedsted-Hansen, J., Kienast, J., Feith Tan, N. Research Sun, 01 Jan 2023 07:29:07 +0100 90f8d773-a40c-43f2-b9c8-c51d909dab29 <![CDATA[Decision-making in committees]]> Maaser, N. F. Research Fri, 01 Jan 2010 07:29:07 +0100 5d8a9d25-47d8-4261-9ac0-127dc703d6bd <![CDATA[Festskrift til Palle Bo Madsen]]> Research Fri, 01 Jan 2021 07:29:08 +0100 d9ea1d10-9159-46df-afe5-cdbbf94c3eb6 <![CDATA[Dansk og international køberet]]> Kristensen, L. H., Karstoft, S., Iversen, T. Research Sat, 01 Jan 2022 07:29:08 +0100 965f3548-72e7-4e5a-8f90-2d850901d4f1 <![CDATA[Entreprise]]> Iversen, T. Research Tue, 01 Jan 2019 07:29:08 +0100 43a28176-4d60-49ec-8d75-74a087d6cf32 <![CDATA[Jura som universitetsfag]]> Iversen, T. Research Fri, 01 Jan 2021 07:29:08 +0100 15e1edf3-2f48-45df-b370-ab243b222487 <![CDATA[Beskyttelsen af grundrettigheder i Danmark og det danske EU-medlemskab]]> Vedsted-Hansen, J. Research Sun, 01 Jan 2023 07:29:08 +0100 4ffd75bc-66c2-4d97-8e5b-4bfc73ce3321 <![CDATA[Danish Decision on the Agency PE Clause of the OECD Model (2017)]]> Laursen, A. N. Research Sun, 01 Jan 2023 07:29:08 +0100 3e2bd152-7c02-410c-8a03-dc698ae904db <![CDATA[Tvangsbegreber i sundhedsretten]]> Madsen, H. B. Research Tue, 07 Feb 2023 07:29:08 +0100 b5c206ab-338d-48e9-afcf-24c8787e0ba1 <![CDATA[REFLEKTIONER I ANLEDNING AF 50 ÅRS DANSK MEDLEMSKAB AF EU]]> Neergaard, U., Sørensen, K. E. Communication Sun, 01 Jan 2023 07:29:08 +0100 d8220435-adae-410d-9e79-c597c2714e2d <![CDATA[The role of regulation in geothermal energy in the UK]]> McClean, A., Pedersen, O. W. Research Wed, 01 Feb 2023 07:29:08 +0100 a14c8e08-9fb7-4baf-986c-46aad6cc068c <![CDATA[Ligningslovens § 33 A og ophold i udlandet]]> Laursen, A. N. Research Sun, 01 Jan 2023 07:29:08 +0100 c80bc8a1-9b51-4e6f-926e-f86cd5ca1a6b <![CDATA[Anti-fragmentering og fast driftssted]]> Laursen, A. N. Research Sun, 01 Jan 2023 07:29:08 +0100 0d633ea9-25c3-4a39-99ec-7e68cdade47e <![CDATA[EU-Karnov 2022]]> Research Sat, 01 Oct 2022 07:29:08 +0200 b5d36559-bb21-4559-a03e-dc0a0316630d <![CDATA[En god overgang til voksenlivet]]> Naur, E., Adolphsen, C. Research Sat, 01 Jan 2022 07:29:08 +0100 ce23032f-bcdc-4a38-bc36-f3cb3ddf08a4 <![CDATA[Indledning]]> Neergaard, U., Sørensen, K. E. Communication Sun, 01 Jan 2023 07:29:08 +0100 02e4f0e9-aefe-400f-9cc9-4fdf3beaa024 <![CDATA[Centros og selskabers fri bevægelighed]]> Sørensen, K. E. Research Sun, 01 Jan 2023 07:29:08 +0100 e3a9b44a-499f-459c-a600-7ee84dff0c22 <![CDATA[Regulation BIa:]]> Steensgaard, K. Communication Fri, 01 Apr 2022 07:29:08 +0200 a4739d7c-0b47-42e9-ac65-bab334fdc48d <![CDATA[Country Report Gender Equality - Denmark 2022]]> Munkholm, N. V. Research Tue, 01 Nov 2022 07:29:08 +0100 585ebf9d-58a1-4164-930e-31b4d0724105 <![CDATA[Ansættelsesforhold]]> Munkholm, N. V. Research Mon, 01 Aug 2022 07:29:08 +0200 d0b2c779-b7e0-4b2b-9779-3b7f36d5ae0c <![CDATA[Key note: Temporary agency work - the role of social partners]]> Munkholm, N. V. Research Mon, 01 May 2023 07:29:08 +0200 12862161-6aca-43cc-8bc4-e1dbbf4633d4 <![CDATA[Anmeldelse af Henrik Karl Nielsen: Arbejdsklausuler i offentlige kontrakter. Karnov 2022]]> Munkholm, N. V. Research Sat, 01 Apr 2023 07:29:08 +0200 84af1f60-17b1-490a-80a0-fdd69e240747 <![CDATA[Privacy at Work in Denmark]]> Munkholm, N. V. Research Mon, 01 May 2023 07:29:08 +0200 fdde9b90-f7a6-455a-9e04-0a626d2065c3 <![CDATA[Lønmodtager/arbejdstagerbegrebet i dansk arbejds- og ansættelsesret - med fokus på platformsarbejde]]> Munkholm, N. V., Jacqueson, C., Schjøler, C. H. Research Fri, 01 Apr 2022 07:29:08 +0200 926c45b3-219f-447a-b46c-0a801b1a055d <![CDATA[National report on Denmark 2022]]> Munkholm, N. V., Cleveland Bolding, L. Research Tue, 01 Feb 2022 07:29:08 +0100 2f7ac14f-3921-41a4-b9ed-a84a23b1e66a <![CDATA[25. Social- og arbejdsmarkedspolitikken. Socialfonden (Art 151-167)]]> Munkholm, N. V., Lind, M. G. Research Tue, 01 Nov 2022 07:29:08 +0100 1bcdf79b-8bf9-4789-90ac-034fbe0f66b6 <![CDATA[Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT)]]> Howard, J. F., Bril, V., Vu, T., et al. Background: There is an unmet need for treatment options for generalised myasthenia gravis that are effective, targeted, well tolerated, and can be used in a broad population of patients. We aimed to assess the safety and efficacy of efgartigimod (ARGX-113), a human IgG1 antibody Fc fragment engineered to reduce pathogenic IgG autoantibody levels, in patients with generalised myasthenia gravis. Methods: ADAPT was a randomised, double-blind, placebo-controlled, phase 3 trial done at 56 neuromuscular academic and community centres in 15 countries in North America, Europe, and Japan. Patients aged at least 18 years with generalised myasthenia gravis were eligible to participate in the study, regardless of anti-acetylcholine receptor antibody status, if they had a Myasthenia Gravis Activities of Daily Living (MG-ADL) score of at least 5 (>50% non-ocular), and were on a stable dose of at least one treatment for generalised myasthenia gravis. Patients were randomly assigned by interactive response technology (1:1) to efgartigimod (10 mg/kg) or matching placebo, administered as four infusions per cycle (one infusion per week), repeated as needed depending on clinical response no sooner than 8 weeks after initiation of the previous cycle. Patients, investigators, and clinical site staff were all masked to treatment allocation. The primary endpoint was proportion of acetylcholine receptor antibody-positive patients who were MG-ADL responders (≥2-point MG-ADL improvement sustained for ≥4 weeks) in the first treatment cycle. The primary analysis was done in the modified intention-to-treat population of all acetylcholine receptor antibody-positive patients who had a valid baseline MG-ADL assessment and at least one post-baseline MG-ADL assessment. The safety analysis included all randomly assigned patients who received at least one dose or part dose of efgartigimod or placebo. This trial is registered at (NCT03669588); an open-label extension is ongoing (ADAPT+, NCT03770403). Findings: Between Sept 5, 2018, and Nov 26, 2019, 167 patients (84 in the efgartigimod group and 83 in the placebo group) were enrolled, randomly assigned, and treated. 129 (77%) were acetylcholine receptor antibody-positive. Of these patients, more of those in the efgartigimod group were MG-ADL responders (44 [68%] of 65) in cycle 1 than in the placebo group (19 [30%] of 64), with an odds ratio of 4·95 (95% CI 2·21–11·53, p<0·0001). 65 (77%) of 84 patients in the efgartigimod group and 70 (84%) of 83 in the placebo group had treatment-emergent adverse events, with the most frequent being headache (efgartigimod 24 [29%] vs placebo 23 [28%]) and nasopharyngitis (efgartigimod ten [12%] vs placebo 15 [18%]). Four (5%) efgartigimod-treated patients and seven (8%) patients in the placebo group had a serious adverse event. Three patients in each treatment group (4%) discontinued treatment during the study. There were no deaths. Interpretation: Efgartigimod was well tolerated and efficacious in patients with generalised myasthenia gravis. The individualised dosing based on clinical response was a unique feature of ADAPT, and translation to clinical practice with longer term safety and efficacy data will be further informed by the ongoing open-label extension. Funding: argenx.

Research Thu, 01 Jul 2021 07:29:08 +0200 be960ec5-522c-4849-b4e6-e460ee1d0fb6
<![CDATA[50 års dansk EU-medlemskab har sat tydelige spor overalt]]> Neergaard, U., Sørensen, K. E. Communication Sun, 01 Jan 2023 07:29:08 +0100 bf71ebfa-fce4-4176-8fba-bbaf23ae303f <![CDATA[Virksomhedspant i en insolvensretlig belysning]]> Søholm Lindekilde, L. Research Thu, 01 Dec 2022 07:29:08 +0100 df2c8ce5-96cb-4bc1-921b-a478d8f2008e <![CDATA[Ekspropriationserstatning og naboret ( U 2021.1195 H )]]> Revsbech, K. Research Tue, 01 Mar 2022 07:29:08 +0100 aaa51ed6-09f1-4d13-9f40-cc944851eb45 <![CDATA[En højesterets dom om valutaspekulation]]> Jørgensen, T., Tanggaard, C. Research Thu, 01 Dec 2022 07:29:08 +0100 fab8fbcb-75f0-4503-86a5-38422a2991ff <![CDATA[Kommentar til Arkivloven]]> Terkelsen, O. Research Fri, 01 Jan 2021 07:29:08 +0100 413b3af9-475c-432e-9a14-db31b9e1e614